› 4f3f

X-ray diffraction
2.65Å resolution

Crystal Structure of Msln7-64 MORAb-009 FAB complex

Released:
DOI: 10.2210/pdb4f3f/pdb
PDB entry 4f3f coloured by chain, front view.
PDB entry 4f3f coloured by chain, side view.
PDB entry 4f3f coloured by chain, top view.
Source organisms:
Primary publication:
Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
Ma J, Tang WK, Esser L, Pastan I, Xia D
J Biol Chem 287 33123-31 (2012)
PMID: 22787150

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-212002 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
MORAb-009 Fab light chain Chain: A
Molecule details ›
Chain: A
Length: 213 amino acids
Theoretical weight: 23.24 KDa
Source organism: Mus musculus
Expression system: Escherichia coli
Structure domains: Immunoglobulins
MORAb-009 Fab heavy chain Chain: B
Molecule details ›
Chain: B
Length: 231 amino acids
Theoretical weight: 24.42 KDa
Source organism: Mus musculus
Expression system: Escherichia coli
Structure domains: Immunoglobulins
Mesothelin, cleaved form Chain: C
Molecule details ›
Chain: C
Length: 69 amino acids
Theoretical weight: 8.05 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q13421 (Residues: 302-359; Coverage: 10%)
Gene names: MPF, MSLN
Structure domains: Transferase, Pyrimidine Nucleoside Phosphorylase; Chain A, domain 3

Ligands and Environments

No bound ligands
1 modified residue:
Ligand PCA 1 x PCA

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 22-ID
Spacegroup: P64
Unit cell:
a: 146.163Å b: 146.163Å c: 80.874Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.179 0.177 0.222
Expression system: Escherichia coli

Quick links

Citations

7 review citations

Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.
Boussios et al. (2018)
6 more

8 mentions without citation

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty et al. (2020)
7 more